Short Interest in Precipio, Inc. (NASDAQ:PRPO) Increases By 21.0%

Precipio, Inc. (NASDAQ:PRPO) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 4,991 shares, a growth of 21.0% from the December 15th total of 4,124 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average trading volume of 8,187 shares, the days-to-cover ratio is presently 0.6 days. Based on an average trading volume of 8,187 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.3% of the shares of the company are sold short.

Institutional Trading of Precipio

Several hedge funds and other institutional investors have recently bought and sold shares of PRPO. Susquehanna International Group LLP purchased a new position in shares of Precipio during the third quarter valued at approximately $194,000. Evernest Financial Advisors LLC purchased a new position in Precipio during the 3rd quarter valued at about $374,000. Topline Capital Management LLC bought a new stake in Precipio during the third quarter worth about $1,158,000. Finally, AMH Equity Ltd grew its holdings in Precipio by 370.1% in the third quarter. AMH Equity Ltd now owns 131,100 shares of the biotechnology company’s stock worth $2,332,000 after purchasing an additional 103,210 shares during the period. Institutional investors own 10.45% of the company’s stock.

Precipio Price Performance

Shares of PRPO stock traded down $0.50 during trading hours on Monday, reaching $23.50. The stock had a trading volume of 15,817 shares, compared to its average volume of 6,764. The stock’s fifty day simple moving average is $23.49 and its 200 day simple moving average is $19.28. The firm has a market capitalization of $41.13 million, a PE ratio of -28.66 and a beta of 1.12. Precipio has a 12 month low of $3.90 and a 12 month high of $28.50. The company has a current ratio of 1.27, a quick ratio of 1.10 and a debt-to-equity ratio of 0.06.

Precipio (NASDAQ:PRPO) last posted its earnings results on Friday, November 14th. The biotechnology company reported ($0.05) EPS for the quarter. Precipio had a negative return on equity of 10.07% and a negative net margin of 5.50%.The business had revenue of $6.77 million for the quarter.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PRPO. Weiss Ratings restated a “sell (d-)” rating on shares of Precipio in a research note on Wednesday, October 8th. Wall Street Zen lowered shares of Precipio from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.